Biocon's net profit for Q1FY25 surged to ₹660 crore, up from ₹101 crore the previous year, primarily due to a one-time gain from selling Biocon Biologics' domestic branded formulation business. Revenue remained flat at ₹3,433 crore. Core EBITDA saw a decline, although overall EBITDA improved significantly due to the one-off gain.
